Literature DB >> 25431369

Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review.

Lewis Stevens1, Samir Pathak, Quentin M Nunes, Sanjay Pandanaboyana, Christian Macutkiewicz, Neil Smart, Andrew M Smith.   

Abstract

BACKGROUND: Better pre-operative risk stratification may improve patient selection for pancreatic resection in pancreatic cancer. C-reactive protein (CRP) and the neutrophil-lymphocyte ratio (NLR) have demonstrated prognostic value in some cancers. The role of CRP and NLR in predicting outcome in pancreatic cancer after curative resection is not well established.
METHODS: An electronic search of MEDLINE, EMBASE and CINAHL was performed to identify studies assessing survival in patients after pancreatic cancer resection with high or low pre-operative CRP or NLR. Systematic review was undertaken using the PRISMA protocol.
RESULTS: In total, 327 studies were identified with 10 reporting on survival outcomes after a pancreatic resection in patients with high or low CRP, NLR or both. All but one paper showed a trend of lower inflammatory markers in patients with longer survival. Three studies from six showed low CRP to be independently associated with increased survival and two studies of eight showed the same for NLR. All studies were retrospective cohort studies of low to moderate quality. DISCUSSION: Inflammatory markers might prove useful guides to the management of resectable pancreatic cancer but, given the poor quality of evidence, further longitudinal studies are required before incorporating pre-operative inflammatory markers into clinical decision making.
© 2014 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25431369      PMCID: PMC4368390          DOI: 10.1111/hpb.12355

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  45 in total

1.  Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.

Authors:  G Garcea; N Ladwa; C P Neal; M S Metcalfe; A R Dennison; D P Berry
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

Review 2.  From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation.

Authors:  Charlotte Servais; Neta Erez
Journal:  J Pathol       Date:  2012-11-20       Impact factor: 7.996

3.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

Review 4.  Cancer-related inflammation.

Authors:  Juliana Candido; Thorsten Hagemann
Journal:  J Clin Immunol       Date:  2012-12-09       Impact factor: 8.317

Review 5.  Borderline resectable pancreatic cancer: on the edge of survival.

Authors:  Gregory M Springett; Sarah E Hoffe
Journal:  Cancer Control       Date:  2008-10       Impact factor: 3.302

6.  Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma.

Authors:  Masanori Ikeda; Shoji Natsugoe; Shinichi Ueno; Masamichi Baba; Takashi Aikou
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

7.  A study of inflammation-based predictors of tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.

Authors:  Mark Krauthamer; Keren Rouvinov; Samuel Ariad; Sofia Man; Shlomo Walfish; Ilia Pinsk; Ignatio Sztarker; Tatiana Charkovsky; Konstantin Lavrenkov
Journal:  Oncology       Date:  2013-06-29       Impact factor: 2.935

8.  Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas.

Authors:  J K Pine; K G Fusai; R Young; D Sharma; B R Davidson; K V Menon; S H Rahman
Journal:  Eur J Surg Oncol       Date:  2009-01-06       Impact factor: 4.424

9.  Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.

Authors:  J Heinrich; H Schulte; R Schönfeld; E Köhler; G Assmann
Journal:  Thromb Haemost       Date:  1995-03       Impact factor: 5.249

10.  A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer.

Authors:  M J Proctor; D C McMillan; D S Morrison; C D Fletcher; P G Horgan; S J Clarke
Journal:  Br J Cancer       Date:  2012-07-24       Impact factor: 7.640

View more
  30 in total

1.  Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer.

Authors:  Yuan Gao; Wen-Jie Wang; Qiaoming Zhi; Meng Shen; Min Jiang; Xiaojie Bian; Fei-Ran Gong; Chong Zhou; Lian Lian; Meng-Yao Wu; Jun Feng; Min Tao; Wei Li
Journal:  Oncotarget       Date:  2017-09-27

2.  Prognostic impact of interleukin-6 and C-reactive protein on patients with breast cancer.

Authors:  Tatsuo Shimura; Masahiko Shibata; Kenji Gonda; Yuko Murakami; Masaru Noda; Kazunoshin Tachibana; Noriko Abe; Tohru Ohtake
Journal:  Oncol Lett       Date:  2019-03-21       Impact factor: 2.967

3.  Is there a correlation between preoperative neutrophil-to-lymphocyte, platelet-to-lymphocyte, and lymphocyte-to-monocyte ratios and postoperative pain in video-assisted thoracoscopic surgery?

Authors:  Gülay Ülger; Ramazan Baldemir; Musa Zengin; Hilal Sazak; Ali Alagöz
Journal:  Medicine (Baltimore)       Date:  2022-05-27       Impact factor: 1.817

4.  Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.

Authors:  Evan S Glazer; Omar M Rashid; Jose M Pimiento; Pamela J Hodul; Mokenge P Malafa
Journal:  Surgery       Date:  2016-07-20       Impact factor: 3.982

5.  The novel index using preoperative C-reactive protein and neutrophil-to-lymphocyte ratio predicts poor prognosis in patients with pancreatic cancer.

Authors:  Tomohiko Taniai; Koichiro Haruki; Kenei Furukawa; Shinji Onda; Jungo Yasuda; Yoshihiro Shirai; Takeshi Gocho; Mitsuru Yanagaki; Ryoga Hamura; Hiroaki Shiba; Toru Ikegami
Journal:  Int J Clin Oncol       Date:  2021-06-10       Impact factor: 3.402

6.  The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases.

Authors:  Kota Arima; Hirohisa Okabe; Daisuke Hashimoto; Akira Chikamoto; Akira Tsuji; Kensuke Yamamura; Yuki Kitano; Risa Inoue; Takayoshi Kaida; Takaaki Higashi; Katsunobu Taki; Katsunori Imai; Yoshihiro Komohara; Toru Beppu; Motohiro Takeya; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2016-03-29       Impact factor: 3.402

7.  Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or metastatic pancreatic cancer receiving cytotoxic chemotherapy.

Authors:  Giuseppe A Colloca; Antonella Venturino; Domenico Guarneri
Journal:  Med Oncol       Date:  2018-10-29       Impact factor: 3.064

8.  Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma.

Authors:  Aino Salmiheimo; Harri Mustonen; Ulf-Håkan Stenman; Pauli Puolakkainen; Esko Kemppainen; Hanna Seppänen; Caj Haglund
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

9.  Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study.

Authors:  Christelle d'Engremont; Dewi Vernerey; Anne-Laure Pointet; Gaël Simone; Francine Fein; Bruno Heyd; Stéphane Koch; Lucine Vuitton; Stefano Kim; Marine Jary; Najib Lamfichek; Celia Turco; Zaher Lakkis; Anne Berger; Franck Bonnetain; Julien Taieb; Philippe Bachellier; Christophe Borg
Journal:  BMC Cancer       Date:  2016-10-26       Impact factor: 4.430

10.  Pretreatment C-reactive protein/albumin ratio is associated with poor survival in patients with stage IB-IIA cervical cancer.

Authors:  Weiwei Zhang; Kejun Liu; Bin Ye; Weijiang Liang; Yazhou Ren
Journal:  Cancer Med       Date:  2017-11-28       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.